IPCA Laboratories, a Mumbai-based drugmaker, on February 4, reported a 35.42% rise in its consolidated net profit to Rs 2,675 million for the quarter-ended December.

The company had posted a net profit of Rs 1,975.4 million for the corresponding period of the previous fiscal.

Consolidated revenue from operations of the company grew 16.24% to Rs 14,098.3 million for the quarter compared to Rs 12,128.6 million for the same period a year ago.

EBITDA gained 34.1% at Rs 3,669 million in December 2020 against Rs 2,737 million in December 2019.

Total expenses increased 10.53% to Rs 10,987.1 million for the quarter compared to Rs 9,940.4 million for the same period a year ago.

IPCA Laboratories EPS increased to Rs 21.09 in December 2020 compared to Rs 15.63 in December 2019.

 Shares of the company declined Rs 37.30, or 1.83%, to settle  at  Rs 2,000.65.  The total volume of shares traded  was 30,978 at  the BSE (Thursday).